Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.

Journal: The Medical letter on drugs and therapeutics 2005;47(1207):36

PMID: 15843784

Full Text on Medical Letter on Drugs and Therapeutics View on PubMed

Abstract

Palifermin (Kepivance) is a recombinant keratinocyte growth factor that decreases the incidence and duration of severe oral mucositis (OM) in patients with hematologic malignancies receiving myelotoxic chemotherapy and hematopoietic stem cell support. It appears to be well tolerated and could decrease use of opioid analgesics and total parenteral nutrition in these patients.

Link outs

Subscription / membership required

Full Text Sources:

https://www.medicalletter.org/scripts/articlefind....

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Combined Modality Therapy, Fibroblast Growth Factor 7, Fibroblast Growth Factors, Humans, Mouth Mucosa, Randomized Controlled Trials as Topic, Stomatitis, Whole-Body Irradiation